0001209191-20-014224.txt : 20200228
0001209191-20-014224.hdr.sgml : 20200228
20200228200107
ACCESSION NUMBER: 0001209191-20-014224
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200228
FILED AS OF DATE: 20200228
DATE AS OF CHANGE: 20200228
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Howton David T
CENTRAL INDEX KEY: 0001529297
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 20673734
MAIL ADDRESS:
STREET 1: VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 130 WAVERLY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 930797222
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-274-4000
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-28
0
0000873303
Sarepta Therapeutics, Inc.
SRPT
0001529297
Howton David T
215 FIRST STREET, SUITE 415
CAMBRIDGE
MA
02142
0
1
0
0
EVP, General Counsel
Common Stock
2020-02-28
4
A
0
6700
0.00
A
31871
D
Stock option (right to buy)
114.47
2020-02-28
4
A
0
37500
0.00
A
2030-02-28
Common Stock
37500
37500
D
The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of
the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25%
will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the
fourth anniversary of the grant date.
25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and
become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of
the date of grant.
/s/ David Tyronne Howton
2020-02-28